Seven-Day Nonbismuth Containing Quadruple Therapy Could Achieve a Grade “A” Success Rate for First-Line Helicobacter pylori Eradication

Table 4

Univariate analysis of the clinical factors influencing the efficacy of H. pylori eradication.

Principle parameter		EACM			EAC
		Case number	Eradication rate (%)	value	Case number	Eradication rate (%)	value
Age	<60 years	75/78	96.1	0.578	52/64	81.2	0.496
	≥60 years	13/14	92.8		21/28	75.0
Sex	Female	44/47	93.6	0.328	33/46	71.1	0.071
	Male	44/45	97.8		40/46	86.9
Smoking		74/78	94.9	0.386	61/78	78.2	0.523
		14/14	100.0		12/14	85.7
Alcohol consumption		69/72	95.8	0.872	61/78	78.2	0.523
		19/20	95.0		12/14	85.7
Previous history of peptic ulcer		74/78	94.9	0.386	57/73	78.1	0.557
		14/14	100.0		16/19	84.2
Compliance	Good	92/92	100.0	—	92/92	100.0	—
	Poor	0	0		0	0
H. pylori culture ()
Amoxicillin	Susceptible	31/34	91.2	—	15/33	45.4	0.367
	Resistance	0	—		0/1	0
Clarithromycin	Susceptible	29/30	96.7	0.002	15/15	100	<0.001
	Resistance	2/4	50.0		0/19	0
Metronidazole	Susceptible	23/23	100	0.009	11/24	45.8	0.755
	Resistance	8/11	72.7		4/10	40.0
Dual resistance	Absent	30/31	96.8	<0.001	15/28	53.6	<0.001
	Present	1/3	33.3		0/6	0

EACM group: 7-day esomeprazole/amoxicillin/clarithromycin/metronidazole therapy; EAC group: 7-day standard esomeprazole/amoxicillin/clarithromycin triple therapy.